title: Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease.
abstract: It has been demonstrated that consecutive samples of induced sputum may differ with respect to cellular composition. The aim of this study was to compare two sequential sputum samples in patients with chronic obstructive pulmonary disease (COPD) and asthma with different severity. Two sputum inductions were performed 30 min apart and processed separately in healthy subjects (n=11), patients with moderate to severe COPD (n=10), asthmatics treated with beta2-agonists alone (group 1, n=11), inhaled steroids (group 2, n=12) or systemic steroids (group 3, n=7). In healthy subjects and asthma group 2, percentages of neutrophils decreased significantly between the two sputum inductions but did not change in COPD and asthma group 3. Percentages of eosinophils did not change significantly in any group of patients. Concentrations of interleukin (IL)-8 decreased significantly in the control group and asthma groups 1 and 2 but not in asthma group 3 and the COPD group. These data demonstrate differences in sputum composition between two consecutive samples which were most pronounced in healthy subjects. Therefore, pooling of sputum samples may affect the results, particularly in healthy subjects, in contrast to subjects with more severe asthma or chronic obstructive pulmonary disease. These findings may be suggestive of differences in the distribution of inflammation along the airways between distinct airway diseases.
authors.affiliation: Krankenhaus Grosshansdorf, Zentrum für Pneumologie und Thoraxchirurgie, LVA Freie und Hansestadt Hamburg, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Richter
authors.forename: O
authors.initials: O
authors.lastname: Holz
authors.forename: R A
authors.initials: RA
authors.lastname: Jörres
authors.forename: M
authors.initials: M
authors.lastname: Mücke
authors.forename: H
authors.initials: H
authors.lastname: Magnussen
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000378:metabolism / Q000473:pathology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012129:Respiratory Function Tests; D012260:Ribonucleases; D013183:Sputum / Q000737:chemistry / Q000378:metabolism*
chemical_list: D000318:Adrenergic beta-Agonists; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D005938:Glucocorticoids; D016209:Interleukin-8; D011239:Prednisolone; D012260:Ribonucleases; D000420:Albuterol